TerminatedPhase 3

Tanezumab In Osteoarthritis Of The Hip Or Knee

Stopped: See termination reason in detailed description.

United States614 participantsStarted 2009-10-30

Plain-language summary

The purpose of the study is to test the efficacy and safety of 2 doses of tanezumab compared to oxycodone CR and placebo in patients with osteoarthritis

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * osteoarthritis of the knee or hip according to Kellgren-Lawrence x-ray grade of 2 Exclusion Criteria: * pregnancy or intent to become pregnant * BMI greater than 39 * other severe pain, significant cardiac, neurological or psychiatric disease

What they're measuring

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 8: ITT Population

Timeframe: Baseline, Week 8

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 8: Modified Intent-to-Treat (mITT) Population

Timeframe: Baseline, Week 8

Trial details

NCT IDNCT00985621

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-12-13

Results submitted2021-04-20

View on ClinicalTrials.gov More Osteoarthritis trials